Who made September's PBS cut?

Posted 30 August 2022 AM

From 1 September, GSK's Zejula will be listed on the PBS for the treatment of women with newly diagnosed advanced ovarian cancer who have a BRCA mutation.

An estimated 25 per cent of around 1,700 women diagnosed with ovarian cancer every year in Australia have a BRCA mutation, so it's expected around 400 women will be treated with Zejula each year.

To see the whole article, please login